BPC-157 vs Larazotide

BPC-157 and Larazotide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157, a synthetic peptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol), is derived from a protein found in human gastric juice. Extensive preclinical research indicates that BPC-157 exhibits potent regenerative and cytoprotective properties, with studies demonstrating its efficacy in enhancing healing processes across various tissues, including tendons, ligaments, muscles, bones, nerves, and the gastrointestinal tract. Despite these promising findings, human clinical data remains limited, with only three pilot studies conducted as of 2025, focusing on knee pain (n=16), interstitial cystitis (n=12), and intravenous safety (n=2). Regulatory status is noteworthy; the FDA classifies BPC-157 as Category 2, which prohibits compounding, and it is banned by WADA in competitive sports. The peptide is primarily associated with claims of accelerating tendon and ligament healing, repairing gut lining, and reversing NSAID-induced GI damage.

Larazotide (AT-1001) is an 8-amino acid synthetic peptide that functions as a tight junction regulator, specifically targeting intestinal permeability. It is under investigation as an oral adjunct therapy for celiac disease, aimed at mitigating the effects of gluten exposure by reducing intestinal permeability. As the first drug in its class, Larazotide has undergone Phase II clinical trials and a Phase III trial (INN-202, also known as CeDLara), demonstrating its potential in managing celiac disease symptoms. Notably, Larazotide operates locally within the gut without significant systemic absorption, which may limit potential side effects. Originally developed by Alba Therapeutics and later acquired by Innovate Biopharmaceuticals (now 9 Meters Biopharma), Larazotide has shown promise in reducing symptoms during gluten exposure and is generally well tolerated, with adverse event rates comparable to placebo in controlled trials.

Both BPC-157 and Larazotide are being investigated for their roles in gut health, particularly in relation to conditions characterized by increased intestinal permeability. BPC-157's regenerative properties make it a candidate for broader applications in injury recovery, particularly in musculoskeletal tissues. In contrast, Larazotide is specifically focused on celiac disease, where its mechanism of action as a tight junction regulator is critical for managing gluten-induced damage. The distinct yet overlapping research applications highlight the unique contributions each peptide may offer in the field of gastrointestinal health and recovery.

The safety profiles of BPC-157 and Larazotide differ significantly based on available research. For BPC-157, there are no completed randomized controlled trials assessing its safety in humans. Preclinical studies across various species have not identified a toxic or lethal dose threshold, with ranges studied from 6 mcg/kg to 20 mg/kg showing no teratogenic, genotoxic, or anaphylactic effects during necropsy and histopathology. However, the FDA previously classified BPC-157 as Category 2 due to significant safety concerns, although this classification was removed on April 15, 2026, with a PCAC review pending in July 2026 to evaluate compounding eligibility. In contrast, Larazotide has demonstrated a favorable safety profile across Phase I, II, and III trials, with adverse event rates comparable to those of placebo groups and minimal systemic absorption observed at therapeutic doses. This suggests a potentially lower risk profile for Larazotide in clinical settings.